Use of defibrotide in the treatment and prevention of veno-occlusive disease.
about
Dactinomycin-induced Hepatic Sinusoidal Obstruction Syndrome Responding to Treatment with N-acetylcysteine.Maternal malaria induces a procoagulant and antifibrinolytic state that is embryotoxic but responsive to anticoagulant therapy.Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malariaDefibrotide: a Swiss Army knife intervention in the battle against cerebral malaria.Defibrotide for the treatment of sinusoidal obstruction syndrome: evaluation of response to therapy and patient outcomes.Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
P2860
Use of defibrotide in the treatment and prevention of veno-occlusive disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of defibrotide in the treatment and prevention of veno-occlusive disease.
@en
Use of defibrotide in the treatment and prevention of veno-occlusive disease.
@nl
type
label
Use of defibrotide in the treatment and prevention of veno-occlusive disease.
@en
Use of defibrotide in the treatment and prevention of veno-occlusive disease.
@nl
prefLabel
Use of defibrotide in the treatment and prevention of veno-occlusive disease.
@en
Use of defibrotide in the treatment and prevention of veno-occlusive disease.
@nl
P2093
P2860
P356
P1476
Use of defibrotide in the treatment and prevention of veno-occlusive disease.
@en
P2093
Carolyn Revta
Erica Linden
Vincent Ho
P2860
P304
P356
10.1586/EHM.09.30
P577
2009-08-01T00:00:00Z